Drugs for the perioperative control of hypertension: Current issues and future directions

Drugs

Volumn 67, Issue 14, 2007, Pages 2023-2044

  Feneck, Robert ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alpha 1 adrenergic receptor antagonists, therapeutic use; Alpha 2 adrenergic receptor agonists, therapeutic use; Anaesthetics, therapeutic use; Beta adrenergic receptor antagonists, therapeutic use; Calcium channel antagonists, therapeutic use

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANESTHETIC AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; CLONIDINE; DEXMEDETOMIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPEXAMINE; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; ISRADIPINE; LABETALOL; LEVOBUPIVACAINE; METOPROLOL; MIVAZEROL; NICARDIPINE; NIFEDIPINE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PROPRANOLOL; ROPIVACAINE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MONOTHERAPY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; REPEATED DRUG DOSE; REVIEW; SPINAL CORD; TREATMENT RESPONSE;

EID: 34948834767     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767140-00005     Document Type: Review

References (192)

1. Prys-Roberts C, Meloche R, Foex P. Studies of anaesthesia in relation to hypertension I: cardiovascular responses of treated and untreated patients. Br J Anaesth 1971; 43: 122-37
2. Prys-Roberts C, Greene LT, Meloche R, et al. Studies of anaesthesia in relation to hypertension II: haemodynamic consequences of induction and endotracheal intubation. Br J Anaesth 1971; 43: 531-47
3. Prys-Roberts C, Foex P, Biro GP, et al. Studies of anaesthesia in relation to hypertension V: adrenergic beta receptor blockade. Br J Anaesth 1973; 45: 671-81
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52
5. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-7
6. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36
7. Beddhu S, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002; 62: 1776-83
8. Landoni G, Zangrillo A, Franco A, et al. Long term outcome of patients who require renal replacement therapy after cardiac surgery. Eur J Anaesthesiol 2006 Jan; 23: 17-22
9. Soltero ER, Petersen NJ, Earle NR, et al. Long term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: the impact of renal insufficiency and noncardiac vascular disease. J Card Fail 2005 Apr; 11: 206-12
10. Thakar CV, Worley S, Arrigain S, et al. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 2005 Mar; 67: 1112-9
11. Lee TH, Marcantario ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999 Sep 7; 100: 1043-9
12. Kertai MD, Boersma E, Klein J, et al. Optimizing the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch Intern Med 2005 Apr 25; 165: 898-904
13. Boersma E, Kertai MD, Schouten O, et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index. Am J Med 2005 Oct; 118: 1134-41
14. Fitch W, Andrews P. Cerebral blood flow and its regulation: effects of anaesthesia. In: Prys-Roberts C, Brown BR, editors. International practice of anaesthesia. Vol. 1. Oxford: Butterworth Heinemann, 1996: chapter 87, 1-10
15. Dagnino J, Prys-Roberts C. Hypertension, antihypertensive drugs, anaesthetic management of the hypertensive patient. In: Prys-Roberts C, Brown BR, editors. International practice of anaesthesia. Vol 1. Oxford: Butterworth Heinemann, 1996: chapter 38, 1-15
16. Naughton C, Reilly N, Feneck R. Cardiac disease in the non-cardiac surgical population: effect on survival. Br J Nursing 2005 Jul; 14: 718-24
17. Maddox TM. Preoperative cardiovascular evaluation for non-cardiac surgery. Mt Sinai J Med 2005 May; 72: 185-92
18. Mukerjee D, Eagle KA. Perioperative cardiac assessment for non-cardiac surgery: eight steps to the best possible outcome. Circulation 2003 Jun; 107: 2771-4
19. Vuylsteke A, Feneck RO, Joilin-Mellgard A, et al. Perioperative blood pressure control: a prospective survey of patient management in cardiac surgery. J Cardiothorac Vasc Anesth 2000 Jun; 14: 269-73
20. Aronson S, Boisvert D, Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg 2002 May; 94: 1079-84
21. Levy JH, Michelsen L, Shanewise J, et al. Postoperative cardiovascular management. In: Kaplan JA, Reich D, Konstadt S, editors. Cardiac anaesthesia. 4th ed. Philadelphia (PA): WB Saunders, 1999: 1233-59
22. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology 1979; 50: 285-92
23. Prys-Roberts C. Hypertension and anesthesia: fifty years on. Anesthesiology 1979; 50: 281-4
24. Goldman L, Caldera DL, Southwick FS, et al. Cardiac risk factors and complications in non-cardiac surgery. Medicine (Balt) 1978 Jul; 57 (4): 357-70
25. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977 Oct 20; 297 (16): 845-50
26. Howell SJ, Sear JW, Foex P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 2004 Apr; 92: 570-83
27. Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society! Intern Med 2006 Oct; 45:671-4
28. Celis H, Fagard RH. White coat hypertension: a clinical review. Eur J Intern Med 2004 Oct; 15: 348-57
29. vonKnorring J. Postoperative myocardial infarction: a prospective study in a risk group of surgical patients. Surgery 1981; 90: 55-60
30. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA Guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 2002 May; 94 (5): 1052-64
31. Spahn DR, Priebe H-J. Preoperative hypertension: remain wary? 'Yes' - cancel surgery? 'No'. Br J Anaesth 2004; 92: 461-4
32. Casadei B, Abuzeid H. Is there a strong rationale for deferring elective surgery in patients with poorly controlled hypertension? J Hypertens 2005 Jan; 23: 19-22
33. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38: 64-80
34. Ahlquist RP. A study of adrenotropic receptors. Am J Physiol 1948; 153: 586-600
35. Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967 May; 214: 597-8
36. Langer SZ. 25 years since the discovery of presynaptic receptors; present knowledge and future perspectives. Trends Pharmacol Sci 1997; 18: 95-9
37. Bylund D. Alpha-2 adrenoceptor subtypes: are more better? Br J Pharmacol 2005; 144: 159-60
38. Schwinn DA, Caron MG, Leftkowitz RJ. The beta-adrenergic receptor as a model for molecular structure-function relationships in G-protein-coupled receptors. In: Fozzard HA, editor. The heart and cardiovascular system. 2nd ed. New York: Raven Press, 1992: 1657-84
39. Matsui H, Lefkowitz RJ, Caron MG, et al. Localisation of the fourth membrane-spanning domain as a ligand binding site in the human platelet alpha-2 adrenergic receptor. Biochemistry 1989; 28: 4125-30
40. Peden CJ, Prys-Roberts C. The alpha-2 adrenoceptor agonists and anaesthesia. In: Prys-Roberts C, Brown BR, editors. International practice of anaesthesia. Vol. 1. Oxford: Butterworth-Heinemann, 1999: chapter 19, 1-15
41. Stafford-Smith M, Schwinn DA. Cellular biochemistry: receptors, signal transmission and second messengers. In: Prys-Roberts C, Brown BR, editors. International practice of anaesthesia. Vol. 1. Oxford: Butterworth-Heinemann, 1999: chapter 7, 1-22
42. Scheinin M, Schwinn D. The locus coeruleus: site of hypnotic actions of alpha-2 adrenoceptor agonists? Anesthesiology 1992; 76: 873-5
43. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996; 36: 511-44
44. Hieble JP, Ruffolo RR Jr. Possible structural and functional relationships between imidazoline receptors and alpha-2 adrenoceptors. Ann N Y Acad Sci 1995 Jul; 763: 8-21
45. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs 2006; 66 (4): 477-96
46. Widimsky J, Sirotiakova J. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. Curr Med Res Opin 2006 Jul; 22 (7): 1287-94
47. Nishina K, Mikawa K, Uesugi T, et al. Oral clonidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion in children. Paediatr Anaesth 2006 Aug; 16: 834-9
48. De Deyne C, Struys M, Heylen R, et al. Influence of intravenous clonidine pretreatment on anaesthetic requirements during bispectral EEG-guided sevoflurane anesthesia. J Clin Anesth 2000 Feb; 12: 52-7
49. Inomata S, Yaaguchi Y, Toyooka H. The effects of clonidine premedication on sevoflurane requirements and anaesthetic induction time. Anesth Analg 1999 Jul; 89: 204-8
50. Peden CJ, Cloote AH, Stratford N, et al. The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anaesthesia 2001 May; 56: 408-13
51. Khan ZP, Lucas MA, Newton DE, et al. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers 2: auditory and somatosensory evoked responses. Br J Anaesth 1999 Sep; 83: 381-6
52. Muzi M, Goff DR, Kampine JP, et al. Clonidine reduces sympathetic activity but maintains baroreflex responses in normotensive humans. Anesthesiology 1992 Nov; 77 (5): 864-71
53. Wallace AW. Clonidine and modification of perioperative outcome. Curr Opin Anaesthesiol 2006 Aug; 19 (4): 411-7
54. Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 2004 Aug; 101 (2): 284-93
55. Yin YC, Chow LH, Tsao CM, et al. Oral clonidine reduces myocardial ischemia in patients with coronary artery disease undergoing noncardiac surgery. Acta Anaesthesiol Sin 2002 Dec; 40 (4): 197-203
56. Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003 Jun 15; 114 (9): 742-52
57. Virtanen R, Savola J-M, Saano V, et al. Characterisation of the selectivity, specificity and potency of medetomidine as an alpha-2 adrenoceptor agonist. Eur J Pharmacol 1988; 150: 9-14
58. Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999 Dec; 54 (12): 1136-42
59. Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003 Feb; 29 (2): 201-7
60. Martin E, Ramsay G, Mantz J, et al. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med 2003 Jan-Feb; 18 (1): 29-41
61. Ishikawa S, Kugawa S, Neya K, et al. Hemodynamic effects of dexmedetomidine in patients after cardiac surgery. Minerva Chir 2006 Jun; 61 (3): 215-9
62. Yildiz M, Tavlan A, Tuncer S, et al. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation: perioperative haemodynamics and anaesthetic requirements. Drugs R D 2006; 7 (1): 43-52
63. Oliver MF, Goldman L, Julian DG, et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 1999 Oct; 91 (4): 951-61
64. Aantaa R, Jalonen J. Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol 2006 May; 23 (5): 361-72
65. McSPI Europe Research Group. Perioperative sympatholysis: beneficial effects of the alpha 2-adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. Anesthesiology 1997 Feb; 86 (2): 346-63
66. Voulgaropoulos D, Palmer CM. Local anaesthetic pharmacology. In: Prys-Roberts C, Brown BR, editor. International practice of anaesthesia. Oxford: Butterworth-Heinemann, 1999: chapter 2, 1-19
67. Donatelli F, Tran D, Mistraletti G, et al. Epidural analgesia in the post-anaesthesia care unit. Curr Drug Targets 2005 Nov; 6 (7): 795-806
68. Block BM, Liu SS, Rowlingson AJ, et al. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA 2004 Mar 10; 291 (10): 1197-8
69. Flisberg P, Rudin A, Linner R, et al. Pain relief and safety after major surgery: a prospective study of epidural and intravenous analgesia in 2696 patients. Acta Anaesthesiol Scand 2003 Apr; 47 (4): 457-65
70. Ready LB, Loper KA, Nessly M, et al. Postoperative epidural morphine is safe on surgical wards. Anesthesiology 1991 Sep; 75 (3): 452-6
71. de Leon-Casasola OA, Parker B, Lema MJ, et al. Postoperative epidural bupivacaine-morphine therapy: experience with 4,227 surgical cancer patients. Anesthesiology 1994 Aug; 81 (2): 368-75
72. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000; 321: 1493
73. Bonnet F, Marret E. Influence of anaesthetic and analgesic techniques on outcome after surgery. Br J Anaesth 2005; 95 (1): 52-8
74. Summers RJ, McMartin LR. Adrenoceptors and their second messenger systems. J Neurochem 1993 Jan; 60 (1): 10-23
75. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma: views on current management. Eur J Surg Oncol 2003 Aug; 29 (6): 483-90
76. Bembo SA, Elimian A, Waltzer W, et al. Pheochromocytoma in a pregnant woman with a history of intracerebral aneurysms. Am J Med Sci 2005 Jun; 329 (6): 317-9
77. Myklejord DJ. Undiagnosed pheochromocytoma: the anesthesiologist nightmare. Clin Med Res 2004 Feb; 2 (1): 59-62
78. Poulter NR, Wedel H, Dahlof B, et al. ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366 (9489): 907-13
79. Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
80. Mayor S. NICE removes beta blockers as first line treatment for hypertension. BMJ 2006; 333 (7557): 8
81. Miller ED, Fleisher LA. Antihypertensive therapy. In: Kaplan JA, Reich D, Konstadt S, editors. Cardiac anaesthesia. 4th ed. Philadelphia (PA): WB Saunders, 1999: 161-77
82. Katz JD, Croneau LH, Barash PG. Postoperative hypertension: a hazard of abrupt cessation of antihypertensive medication in the postoperative period. Am Heart J 1976; 92: 79-83
83. Pasternack PF, Grossi EA, Baumann FG, et al. Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery. Am J Surg 1989; 158: 113-6
84. Cooper TJ, Clutton-Brock TH, Jones SN, et al. Factors relating to the development of hypertension after cardiopulmonary bypass. Br Heart J 1985 Jul; 54 (1): 91-5
85. Bradley D, Creswell LL, Hogue CW Jr, et al. Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005 Aug; 128 (2 Suppl.): 39-47S
86. DiDomenico RJ, Massad MG. Pharmacologic strategies for prevention of atrial fibrillation after open heart surgery. Ann Thorac Surg 2005 Feb; 79 (2): 728-40
87. Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002 Jul 2; 106 (1): 75-80
88. Amory DW, Grigore A, Amory JK, et al. Neuroprotection is associated with beta-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients. J Cardiothorac Vasc Anesth 2002 Jun; 16 (3): 270-7
89. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocadial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789-94
90. ten Broecke PW, De Hert SG, Mertens E, et al. Effect of preoperative beta-blockade on perioperative mortality in coronary surgery. Br J Anaesth 2003 Jan; 90 (1): 27-31
91. Ferguson TB Jr, Coombs LP, Peterson ED. Society of Thoracic Surgeons National Adult Cardiac Surgery Database. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 2002 May 1; 287 (17): 2221-7
92. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and non-fatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004 Oct; 28 (4): 343-52
93. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005 Jul 28; 353 (4): 349-61
94. Auerbach AD, Goldman L. Beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 2002 Mar 20; 287 (11): 1435-44
95. Taylor RC, Pagliarello G. Prophylactic beta-blockade to prevent myocardial infarction perioperatively in high-risk patients who undergo general surgical procedures. Can J Surg 2003 Jun; 46 (3): 216-22
96. Maggio PM, Taheri PA. Perioperative issues: myocardial ischemia and protection: beta-blockade. Surg Clin North Am 2005 Dec; 85 (6): 1091-102
97. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998 Jan; 88 (1): 7-17
98. Devereaux PJ, Yusuf S, Yang H, et al. Are the recommendations to use perioperative beta blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? CMAJ 2004; 171: 245-7
99. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative β-blockers in non cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 331: 313-21
100. Feringa HH, Bax JJ, Boersma E, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation 2006 Jul 4; 114 (1 Suppl.): I344-9
101. Poldermans D, Bax JJ, Boersma E, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta blocker therapy with tight heart rate control? J Am Coll Cardiol 2006; 48: 964-9
102. Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ 2005 Oct 22; 331 (7522): 932
103. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Anesth Analg 2007 Jan; 104 (1): 15-26
104. Wiesbauer F, Schlager O, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. Anesth Analg 2007 Jan; 104 (1): 27-41
105. Fleisher LA. Perioperative beta-blockade: how best to translate evidence into practice. Anesth Analg 2007 Jan; 104 (1): 1-3
106. Schouten O, Bax JJ, Dunkelgrun M, et al. Pro: beta-blockers are indicated for patients at risk for cardiac complications undergoing noncardiac surgery. Anesth Analg 2007 Jan; 104 (1): 8-10
107. London MJ. Con: beta-blockers are indicated for all adults at increased risk undergoing noncardiac surgery. Anesth Analg 2007 Jan; 104 (1): 11-4
108. Chauvin M, Deriaz H, Viars P. Continuous i.v. infusion of labetalol for postoperative hypertension: haemodynamic effects and plasma kinetics. Br J Anaesth 1987 Oct; 59 (10): 1250-6
109. Sladen RN, Klamerus KJ, Swafford MW, et al. Labetalol for the control of elevated blood pressure following coronary artery bypass grafting. J Cardiothorac Anesth 1990 Apr; 4 (2): 210-21
110. Orlowski JP, Vidt DG, Walker S, et al. The hemodynamic effects of intravenous labetalol for postoperative hypertension. Cleve Clin J Med 1989 Jan-Feb; 56 (1): 29-34
111. Kirshenbaum JM, Kloner RA, Antman EM, et al. Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia. Circulation 1985 Oct; 72 (4): 873-80
112. Singh H, Vichitvejpaisal P, Gaines GY, et al. Comparative effects of lidocaine, esmolol, and nitroglycerin in modifying the hemodynamic response to laryngoscopy and intubation. J Clin Anesth 1995 Feb; 7 (1): 5-8
113. Sharma S, Mitra S, Grover VK, et al. Esmolol blunts the haemodynamic responses to tracheal intubation in treated hypertensive patients. Can J Anaesth 1996 Aug; 43 (8): 778-82
114. Pilli G, Guzeldemir ME, Bayhan N. Esmolol for hypotensive anesthesia in middle ear surgery. Acta Anaesthesiol Belg 1996; 47 (2): 85-91
115. Tempe DK, Mulchandani P, Tandon MS, et al. Control of tachycardia and hypertension following coronary artery bypass graft surgery: efficacy and haemodynamic effects of esmolol. Indian Heart J 1999 May-Jun; 51 (3): 294-300
116. Lim SH, Chin NM, Tai HY, et al. Prophylactic esmolol infusion for the control of cardiovascular responses to extubation after intracranial surgery. Ann Acad Med Singapore 2000 Jul; 29 (4): 447-51
117. Fuhrman TM, Ewell CL, Pippin WD, et al. Comparison of the efficacy of esmolol and alfentanil to attenuate the hemodynamic responses to emergence and extubation. J Clin Anesth 1992 Nov-Dec; 4 (6): 444-7
118. Armanious S, Wong DT, Etchells E, et al. Successful implementation of perioperative beta-blockade utilizing a multidisciplinary approach. Can J Anaesth 2003 Feb; 50 (2): 131-6
119. Brittain RT, Levy GP. A review of the animal pharmacology of labetolol, a combined alpha and beta adrenoceptor blocking drug. Br J Clin Pharmacol 1976; 3: 681-4
120. Singh PP, Dimich I, Sampson I, et al. A comparison of esmolol and labetalol for the treatment of perioperative hypertension in geriatric ambulatory surgical patients. Can J Anaesth 1992 Jul; 39 (6): 559-62
121. Goldberg ME, Cantillo J, Nemiroff MS, et al. Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth 1993 Sep-Oct; 5: 386-91
122. Hill AJ, Feneck RO, Walesby RK. A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. J Cardiothorac Vasc Anesth 1993 Jun; 7: 279-84
123. Gombotz H, Plaza J, Mahla E, et al. DA-1 receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension. Acta Anaesthesiol Scand 1998 Aug; 42: 834-40
124. Reisin E, Huth MM, Nguyen BP, et al. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 1990 Feb; 15: I59-62
125. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993 Aug; 95: 161-8
126. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 1990 Mar; 81: 970-7
127. Aronson S, Goldberg LI, Glock D, et al. Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anaesthsia. J Cardiothorac Vasc Anesth 1991 Feb; 5: 29-32
128. Taylor AA, Shepherd AM, Polvino W, et al. Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. Am J Hypertens 1999 Sep; 12: 906-14
129. Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs 1997 Oct; 54 (4): 634-50
130. Oparil S, Aronson S, Deeb GM, et al. Fenoldopam: a new parenteral antihypertensive: consensus round table on the management of perioperative hypertension and hypertensive crises. Am J Hypertens 1999 Jul; 12: 653-64
131. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007 Jan; 49 (1): 56-68
132. Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006 Mar; 34 (3): 707-14
133. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005 Jun 21; 111 (24): 3230-5
134. Durieux ME, Mounsey JP. Molecular cardiovascular medicine. In: Kaplan JA, Reich D, Konstadt S, editors. Cardiac anaesthesia. 4th ed. Philadelphia (PA): WB Saunders, 1999: 271-96
135. Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003 Dec 16; 139 (12): 1009-17
136. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 2005; 65 Suppl. 2: 1-10
137. Powroznyk AV, Vuylsteke A, Naughton C, et al. Comparison of clevedipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 2003 Sep; 20: 697-703
138. Underwood SM, Davies SW, Feneck RO, et al. Comparison of isradipine with nitroprusside for control of blood pressure following myocardial revascularization: effects on hemodynamics, cardiac metabolism and coronary blood flow. J Cardiothor Vasc Anesth 1991 Aug; 5: 348-56
139. Ruegg PC, David D, Loria Y. Isradipine for the treatment of hypertension following coronary artery bypass graft surgery: a randomized trial versus sodium nitroprusside. Eur J Anaesthesiol 1992 Jul; 9: 293-305
140. Kieler-Jensen N, Jolin-Mellgard A, Norlander M, et al. Coronary and systemic hemodynamic effects of clevedipine, an ultrashort acting calcium antagonist for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand 2000 Feb; 44: 186-93
141. Levy JH. Management of systemic and pulmonary hypertension. Tex Heart Inst J 2005; 32: 467-71
142. Begon C, Dartayet B, Edouard A, et al. Intravenous nicardipine for treatment of intraoperative hypertension during abdominal surgery. J Cardiothorac Anesth 1989 Dec; 3: 707-11
143. Nathan HJ, Laganiere S, Dube L, et al. Intravenous nifedipine to treat hypertension after coronary artery revascularisation surgery: a comparison with sodium nitroprusside. Anesth Anal 1992 Jun; 74: 809-17
144. Sitbon O, Humbert M, Jagot JL. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998 Aug; 12: 265-70
145. Sitbon O, Humbert M, Jais X, et al. Long term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 Jun; 111: 3105-11
146. DiDonato M, Maioli M, Venturi F, et al. Acute hemodynamic effects of intravenous diperdipine, a new dihydropyridine derivative, in coronary heart disease. Am Heart J 1991 Mar; 121: 776-81
147. Weksler N, Klein M, Szendro G, et al. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery? J Clin Anesth 2003 May; 15 (3): 179-83
148. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest 2000 Jul; 118 (1): 214-27
149. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328-31
150. Talbert RL. The challenge of blood pressure management in neurologic emergencies. Pharmacotherapy 2006 Aug; 26: 123-130S
151. Nordlander M, Sjoquist PO, Ericsson H. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 2004; 22 (3): 227-50
152. Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology 2002 May; 96 (5): 1086-94
153. Lincoln TM. Cyclic GMP and mechanisms of vasodilatation. Pharmacol Ther 1989; 41: 479-502
154. Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. J Cardiothorac Vasc Anesth 1992 Oct; 6: 563-7
155. Eyraud D, Brabant S, Nathalie D, et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 1999 May; 88 (5): 980-4
156. Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 1994 Aug; 81 (2): 299-307
157. Bertrand M, Godet G, Meersschaert K, et al. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg 2001 Jan; 92 (1): 26-30
158. Carrel T, Englberger L, Mohacsi P, et al. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000 Sep-Oct; 15 (5): 347-53
159. Pigott DW, Nagle C, Allman K, et al. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth 1999 Nov; 83 (5): 715-20
160. Devbhandari MP, Balasubramanian SK, Codispoti M, et al. Preoperative angiotensin-converting enzyme inhibition can cause severe post CPB vasodilation: current UK opinion. Asian Cardiovasc Thorac Ann 2004 Dec; 12 (4): 346-9
161. Turker H, Donmez A, Zeyneloglu P, et al. Effects of enalaprilat infusion on hemodynamics and renal function in patients undergoing cardiac surgery. Anadolu Kardiyol Derg 2004 Dec; 4 (4): 296-300
162. Schuetz WH, Lindner KH, Georgieff M, et al. The effect of i.v. enalaprilat in chronically treated hypertensive patients during cardiac surgery. Acta Anaesthesiol Scand 1998 Sep; 42 (8): 929-35
163. Vesey CJ, Cole PV. Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside. Br J Anaesth 1985 Feb; 57 (2): 148-55
164. Vesey CJ, Cole PV, Simpson PJ. Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man. Br J Anaesth 1976 Jul; 48 (7): 651-60
165. Marsh MLK, Shapiro HM, Smith RW, et al. Changes in neurologic status and intracranial pressure associated with sodium nitroprusside administration. Anaesthesiology 1979; 51: 336-8
166. Mann T, Cohn PF, Holman LB, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation 1978 Apr; 57 (4): 732-8
167. Royster RL, Zvara DA. Anti-ischemic drug therapy. In: Kaplan JA, Reich D, Konstadt S, et al., editors. Cardiac Anesthesia. 4th ed. Philadelphia (PA): WB Saunders, 1999: 95-130
168. Perusse L, Moll P, Sing C. Evidence that a single gene with gender- and age-dependent effects influences BP determination in a population-based sample. Am J Human Genet 1991; 49: 94-105
169. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh J, Brenner B, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1995: 67-88
170. Lifton R. Molecular genetics of human blood pressure variation. Science 1996; 272: 676-80
171. Ferrannini E. Metabolic abnormalities of hypertension: a lesson in complexity. Hypertension 1991; 18: 636-9
172. Guyton A. BP control: special role of the kidneys and body fluids. Science 1991; 252: 1813-6
173. Jeunemaitre X, Soubrier F, Kotelevtsev Y, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169-80
174. Caulfield M, Lavender P, Farrall M, et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330: 1629-33
175. Jeunemaitre X, Charru A, Chatellier G, et al. M235T variant of the human angiotensinogen gene in unselected hypertensive patients. J Hypertens 1993; 11: S80-1
176. Fornage M, Turner ST, Sing CF, et al. Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. Hum Genet 1995; 96: 295-300
177. Krushkal J, Xiong M, Ferrell R, et al. Linkage and association of
178. Bianchi G, Swales J. Do we need more anti-hypertensive drugs? Lessons from the new biology. Lancet 1995; 345: 1555-7
179. Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens 1998; 7: 217-22
180. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of a-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7
181. Glorioso N, Manunta P, Filigheddu F, et al. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34: 649-54
182. Post W, Larson M, Myers R, et al. The heritability of left ventricular mass: the Framingham Heart Study. Hypertension 1997; 30: 1025-8
183. Harshfield G, Grim C, Hwang C, et al. Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins. Am J Hypertens 1990; 3: 538-43
184. Podgoreanu MV, White WD, Morris RW, et al. Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. Circulation 2006 Jul; 114 (1 Suppl.): I275-81
185. Moretti EW, Morris RW, Podgoreanu M, et al. Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit Care Med 2005 Nov; 33 (11): 2521-6
186. Grocott HP, White WD, Morris RW, et al. Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke 2005 Sep; 36 (9): 1854-8
187. Podgoreanu MV, Michelotti GA, Sato Y, et al. Differential cardiac gene expression during cardiopulmonary bypass: ischemia-independent upregulation of proinflammatory genes. J Thorac Cardiovasc Surg 2005 Aug; 130 (2): 330-9
188. Welsby IJ, Podgoreanu MV, Phillips-Bute B, et al. Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005 Jun; 3 (6): 1206-12
189. Stafford-Smith M, Podgoreanu M, Swaminathan M, et al. Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. Am J Kidney Dis 2005 Mar; 45 (3): 519-30
190. Sugiura S, Seki S, Hideka K, et al. The hemodynamic effects of landiolol, an ultra short acting beta-1 selective blocker, on endotracheal intubation in patients with and without hypertension. Anesth Analg 2007; 104: 124-9
191. Maggioni AP. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther. Epub 2006 Aug 21
192. Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis 2006 Jul-Aug; 49 (1): 16-25